Number of new stock issued during the period.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Subsequent event - (Details) $ in Millions					1 Months Ended
Subsequent event - (Details) $ in Millions	Mar. 04, 2023 item	Mar. 01, 2023 USD ($) item	Jan. 08, 2023 USD ($) item Program shares	Apr. 03, 2022 USD ($) item	Jun. 30, 2019 USD ($) shares	Mar. 31, 2019 USD ($) item Program shares
Neurocrine \| Neurocrine Collaboration Agreement
Subsequent events
Number of collaboration programs \| item						4
Purchase of common stock					$ 5.0	$ 50.0
Purchase of common stock, shares \| shares					4,179,728	4,179,728
Aggregate maximum milestone payments to be received from collaborative partner						$ 170.0
Number of discovery programs \| Program						2
Number of targets \| item						8
Upfront payment					$ 115.0	$ 115.0
Neurocrine \| Neurocrine Collaborative Agreement 2023 \| Subsequent Event.
Subsequent events
Number of collaboration programs \| item			3
Purchase of common stock			$ 39.0
Purchase of common stock, shares \| shares			4,395,588
Upfront payment			$ 136.0
Neurocrine \| Neurocrine Collaborative Agreement 2023 \| Subsequent Event. \| GBA1
Subsequent events
Aggregate maximum milestone payments to be received from collaborative partner			$ 985.0
Number of products \| item			2
Neurocrine \| Neurocrine Collaborative Agreement 2023 \| Subsequent Event. \| Discovery Programs 2023
Subsequent events
Aggregate maximum milestone payments to be received from collaborative partner			$ 175.0
Number of discovery programs \| Program			3
Per Milestone, maximum milestone payments to be received from collaborative partner			$ 275.0
Number of products \| item			1
Neurocrine \| Commercial Milestone \| Neurocrine Collaboration Agreement
Subsequent events
Aggregate maximum milestone payments to be received from collaborative partner						1,100.0
Per Milestone, maximum milestone payments to be received from collaborative partner						$ 275.0
Neurocrine \| Commercial Milestone \| Neurocrine Collaborative Agreement 2023 \| Subsequent Event. \| GBA1
Subsequent events
Per Milestone, maximum milestone payments to be received from collaborative partner			$ 950.0
Novartis Pharma, AG \| Novartis License Agreement
Subsequent events
Number of transgenes \| item				3
Number of targets \| item	2			2
Upfront payment				$ 54.0
Number of options \| item				1
Novartis Pharma, AG \| Novartis License Agreement \| Subsequent Event.
Subsequent events
Number of royalties \| item		2
Number of targets not elected to license a capsid \| item		1
Number of targets \| item		2
Upfront payment		$ 25.0
Period to retain rights		18 months
Additional fee agreed to pay		$ 18.0
Aggregate milestone payments, if exercise rights		$ 12.5